4.7 Article

Validation of Machine Learning-Based Individualized Treatment for Depressive Disorder Using Target Trial Emulation

Journal

JOURNAL OF PERSONALIZED MEDICINE
Volume 11, Issue 12, Pages -

Publisher

MDPI
DOI: 10.3390/jpm11121316

Keywords

anti-depressive agents; machine learning; precision medicine

Funding

  1. NATIONAL HEALTH RESEARCH INSTITUTE, TAIWAN [PH-109-PP-08, CG-110-GP-01]
  2. MINISTRY OF SCIENCE AND TECHNOLOGY OF TAIWAN [MOST 107-2314-B-400-031-MY3, MOST 108-2314-B-002-109-MY2]
  3. TAIWAN MINISTRY OF HEALTH AND WELFARE [MOHW109-MHAOH-M-113-112002]

Ask authors/readers for more resources

This study developed machine learning-based prediction models for personalized pharmacological treatment of patients with depressive disorder, which effectively reduced treatment failure rates.
This study aims to develop and validate the use of machine learning-based prediction models to select individualized pharmacological treatment for patients with depressive disorder. This study used data from Taiwan's National Health Insurance Research Database. Patients with incident depressive disorders were included in this study. The study outcome was treatment failure, which was defined as psychiatric hospitalization, self-harm hospitalization, emergency visits, or treatment change. Prediction models based on the Super Learner ensemble were trained separately for the initial and the next-step treatments if the previous treatments failed. An individualized treatment strategy was developed for selecting the drug with the lowest probability of treatment failure for each patient as the model-selected regimen. We emulated clinical trials to estimate the effectiveness of individualized treatments. The area under the curve of the prediction model using Super Learner was 0.627 and 0.751 for the initial treatment and the next-step treatment, respectively. Model-selected regimens were associated with reduced treatment failure rates, with a 0.84-fold (95% confidence interval (CI) 0.82-0.86) decrease for the initial treatment and a 0.82-fold (95% CI 0.80-0.83) decrease for the next-step. In emulation of clinical trials, the model-selected regimen was associated with a reduced treatment failure rate.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available